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Abstract
Background: During the influenza pandemic of 2009 estimates of symptomatic and asymptomatic infection were needed
to guide vaccination policies and inform other control measures. Serological studies are the most reliable way to measure
influenza infection independent of symptoms. We reviewed all published serological studies that estimated the cumulative
incidence of infection with pandemic influenza H1N1 2009 prior to the initiation of population-based vaccination against
the pandemic strain.
Methodology and Principal Findings: We searched for studies that estimated the cumulative incidence of pandemic
influenza infection in the wider community. We excluded studies that did not include both pre- and post-pandemic
serological sampling and studies that included response to vaccination. We identified 47 potentially eligible studies and
included 12 of them in the review. Where there had been a significant first wave, the cumulative incidence of pandemic
influenza infection was reported in the range 16%–28% in pre-school aged children, 34%–43% in school aged children and
12%–15% in young adults. Only 2%–3% of older adults were infected. The proportion of the entire population infected
ranged from 11%–18%. We re-estimated the cumulative incidence to account for the small proportion of infections that
may not have been detected by serology, and performed direct age-standardisation to the study population. For those
countries where it could be calculated, this suggested a population cumulative incidence in the range 11%–21%.
Conclusions and Significance: Around the world, the cumulative incidence of infection (which is higher than the
cumulative incidence of clinical disease) was below that anticipated prior to the pandemic. Serological studies need to be
routine in order to be sufficiently timely to provide support for decisions about vaccination.
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Introduction
A novel pandemic influenza virus, influenza A H1N1 2009
(pH1N1), was identified in North America in April 2009 and
rapidly spread around the world [1]. Urgent priorities at the start
of the pandemic were to determine the transmissibility of the new
virus and the severity of resulting infections, in order to judge the
appropriate scale of the pandemic response. When anticipating the
arrival of pandemic specific vaccines later in 2009, a key public
health priority at that time was to identify the optimal target
groups for vaccination. This depended on the course of the
pandemic, specifically on the proportion of children that had been
infected, as well as the groups in the population considered to be
most at risk of an adverse outcome.
An early serological study in the US suggested that most of the
population would likely be susceptible to infection with the new
virus, but that older people may have had some protection against
pH1N1 [2]. Consistent with this suggestion were the early
epidemiologic observations of higher clinical attack rates in
children [3]. However influenza virus infections can often be
subclinical, and there may be variation in subclinical infections by
age [4]. In order to fully understand the impact of the 2009
pandemic, and to be able to make comparisons with previous
pandemics and seasonal influenza viruses, estimates of the
cumulative incidence of pH1N1 infection were needed.
Various terms have been used to describe measures of infection.
The ‘attack rate’ describes the cumulative incidence of infection
during a defined disease outbreak [5], although attack rate is
sometimes used to refer only to clinical cases. While ‘rate’ is
generally associated with a measurement of time in the
denominator, ‘attack rate’ does not include time. Similarly the
‘infection rate’ in a specified time refers to the cumulative
incidence of infection, both symptomatic and asymptomatic. In
this review we focus on serological studies that were conducted to
estimate the cumulative incidence of symptomatic and asymp-
tomatic infection.
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Early in the course of the pandemic, a number of approaches
were used to estimate the cumulative incidence of pH1N1
infection. Studies that extrapolated from surveillance data and
surveys required assumptions about the proportion of infected
people who were likely to seek medical care and the proportion of
infections that were asymptomatic [6,7]. However the most
reliable method of estimating the cumulative incidence of
infection, including asymptomatic infections, is serological testing,
given that most infected individuals will develop humoral antibody
at detectable titres 2–3 weeks after infection [4].
Two alternative serological study designs were used to infer the
cumulative incidence of infection with pH1N1. In a longitudinal
design, sera were collected from individuals before and after a
period of pH1N1 circulation, and infected individuals were
identified by comparison of paired antibody titres. Individuals
were typically classified as infected if there was a 4-fold or greater
rise in antibody titre across the paired sera. In a serial cross-
sectional design, the prevalence of antibody at a certain threshold
(seropositivity) was compared before and after a period of pH1N1
circulation. Alternative thresholds were used for comparisons of
seroprevalence, for example 32 [4], 40 [8,9,10] or 10 [11].
Estimates of the cumulative incidence of infection varied,
depending, amongst other things, on the extent of pandemic
spread prior to the availability of vaccination, the sensitivity and
specificity of the tests used and the cut-off titre used to define
infection.
We review serosurveys which estimated the cumulative
incidence of pH1N1 in the general community and were published
between 14 April 2009, when the novel pH1N1 virus was first
identified, and 22 December 2010, which allowed more than a
year since the end of the first pandemic wave in the northern
hemisphere and the end of the season in which pH1N1
predominated in the southern hemisphere, and before a second
season in which pH1N1 circulated. We aimed to compare study
designs and age-specific estimates of the cumulative incidence of
infection with pH1N1 in unvaccinated populations.
Methods
To identify published studies two of the authors (HP, BJC)
designed a search of the database PubMed. One author (HP)
performed an initial search on 22 December 2010 and two authors
(KL, HP) repeated the search on 27 April 2011, using the
PubMedAdvanced Search engine. Articles were searched in ‘All
fields’ using the following terms:
(1) ‘influenza’ or ’flu’ or ‘influenza A’ or ’H1N1’ or ’pH1N1’ or
’A/H1N1’ or ’A(H1N1)’ or ’pdmH1N1’ or ’H1N1pdm’ or
’H1N1swl’ or ’H1N1soiv’ or ’2009(H1N1)’ or ’(H1N1)2009’
(2) ‘infect*’ or ‘antibod*’ or ‘immun*’ or ‘protect* or ‘prevalence’
or ‘attack rate’ or ‘incidence’ or ‘sero*’
(3) (1) and (2).
We limited articles to those published in English between 14
April 2009 and 22 December 2010 (epub dates). The title of each
article identified by the searches was reviewed for relevance.
Abstracts were then reviewed for eligibility based on a broad
description of serological assessment of pH1N1 infection in a
general community setting. In addition we followed up references
in each of the eligible studies and sought information on other
serological studies from expert colleagues in various disciplines.
We also performed regular searches of journals (Eurosurveillance,
PLoS One and PLoS Currents Influenza) which were known to publish
early pandemic influenza studies, including serosurveys. A further
search in Google Scholar using the search terms ‘influenza’ AND
‘2009’ AND ‘antibody’ did not indentify any other studies.
Three of the authors (HK, HP, KL) assessed the eligibility of
studies for inclusion and performed the data extraction. To be
included a study needed to report estimates of the cumulative
incidence of pH1N1 infection from a cross-sectional or longitu-
dinal community-based study. We used conventional criteria for
the definition of pH1N1 infection. In a longitudinal study a four-
fold rise in microneutralisation (MN) or haemagglutination
inhibition (HI) titres (to $40) in paired samples was considered
evidence of infection. In the cross-sectional design titres $32 in a
single HI assay or $40 in a single MN assay were considered to be
evidence of infection. We excluded studies that provided only
estimates of infection after the circulation of pH1N1, with no pre-
pandemic sample, or studies that provided only estimates of the
prevalence of antibodies that cross-reacted to pH1N1 before the
pandemic. We also excluded studies which were unable to
distinguish antibody response due to natural infection from those
due to vaccination, since vaccination would have altered the risk of
infection with pH1N1. Disagreement among authors was resolved
by discussion until a consensus was reached. Data extracted from
the studies included the age-specific estimate of the cumulative
incidence of infection, with confidence intervals if reported, the
timing of serological sampling in relation to the circulation of
pH1N1 and the serological assay(s) used. The months of pandemic
circulation were obtained from surveillance data in the public
domain when not stated in the studies included in the review.
We used the difference in proportions of individuals in specified
age groups with antibody titre .1:40 before and after the first
pandemic wave to estimate the cumulative incidence of infection in
the studies included. However since only around 90% of
convalescent individuals had antibody titre.1:40 [4,12] we inflated
the observed cumulative incidence of infection by 10% when
estimating the true cumulative incidence of infection. We estimated
the direct age-standardization of the cumulative incidence of
infection using the age-specific population data for each country
included in the final review. We used official government data for
2009, except for India, where the most recent age-specific population
data was extracted from the 2001 Census [13,14,15,16,17,18,19].
Since influenza spreads from person to person and the risk of
infection for an individual is not independent from the risk of
infection for others in the population, confidence intervals based
on an independence assumption may underestimate the uncer-
tainty associated with estimates of the cumulative incidence of
infection from serologic studies [20]. We used an approach which
accounts for this non-independence to re-estimate confidence
intervals for the estimates of the cumulative incidence of infection.
The variance of the cumulative incidence of infection was
estimated using the equation below:
Var1~
r3(1{r)zh2r(1{r)2 ln2 (1{
r
1{q
)
N½rz(1{r) ln (1{r
q
)2
,
where r is the estimated mean age-standardized cumulative
incidence of infection, q is the proportion of individuals with pre-
existing immunity, and h refers to the coefficient of variation of the
generation time of influenza. h~0:41 was applied in the
calculation based on the contact tracing data collected in the
Netherlands [20]. N represents the sample size of the population of
interest. We also considered the uncertainty introduced by the
diagnostic method in the study by applying the equation to
estimate the variance [21]:
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Var2~
r(1{r)
N(azb{1)
,
where a and b denote the sensitivity and specificity of the
diagnostic method of interest, which were assumed to be 0.9 and
1.0, respectively, in our analyses. The variance for the estimated
CII was then given by Var1 + Var2. The re-calculated confidence
intervals assumed simple random sampling.
We report the original results from the studies and compare
these with our revised estimates of the cumulative incidence of
infection with re-calculated confidence intervals.
Results
Studies identified
The search identified 2748 citations. One study was identified
through a collaborative project [8] and two studies were identified
through reference checking [22,23]. We identified 47 relevant
published studies (Figure 1). A total of 35 studies were excluded.
Four were commentaries and letters regarding pH1N1 serological
studies [24,25,26,27], two studies were duplicates [28,29], and 29
studies did not match our inclusion criteria. These studies were
conducted in Canada [30], China [31,32,33,34,35,36], England
[37], Finland [38,39], France [22], Germany [40], Hong Kong
[12], India [11], Iran [41], Italy [42], Japan [23], Scotland [43],
Singapore [44,45,46,47,48], Taiwan [49,50,51], the United States
[2,52], and a multi-location study that included the United States,
Costa Rica, Europe and Japan [53]. We identified one further
study on pre-existing pH1N1 immunity in the general population
that examined only the molecular basis for immunity [54]. This
study was not considered further in the review. The specific
reasons for exclusion of all studies are outlined in Table S1.
Studies included in the review
Twelve studies were included in the review (Table 1). These
studies were conducted in Australia [8,9,55,56], Canada [57],
England [4], Hong Kong [10,58], India [59], New Zealand [60],
Norway [61], and Singapore [62]. Not all studies included all age
groups, with the absence of children being the most common
omission (Table 1).
All studies included in the review included data on serum
samples collected before and after the circulation of pH1N1, with
some studies sampling at more than one time after the detection of
pH1N1 circulation (Table 1). Circulation of pH1N1 occurred
between May and November 2009 in all countries, independent of
whether these countries were in the tropics or the temperate
northern and southern hemispheres. Only in Norway was there no
significant circulation of pH1N1 in any age group in the first wave
during summer [61], while there appeared to be no significant
circulation among adults in the study from England in the first
wave and little significant circulation outside London prior to the
second wave [4,37].
The most common sampling strategy used convenience samples
of residual diagnostic sera, often sourced from the laboratory in
which the pandemic serosurvey was performed (Table 1). The
studies from Canada [57], England [4], New South Wales [9],
Western Australia [8], Norway [61] and the small study from
Hong Kong [58] used residual diagnostic sera for both pre- and
post-pandemic samples while the studies from India [59] and New
Zealand [60] used residual diagnostic sera only for the pre-
pandemic samples.
The study from Australia [55] used residual plasma from blood
donors, while the large study from Hong Kong [10] included
blood donors as only one of its sampling strategies. The large
Hong Kong study also took advantage of an existing population-
based cohort of children in addition to a sample of hospital
outpatients. In Singapore existing cohorts of adults were sampled
sequentially [62]. The study from India included a range of
samples in its post-pandemic samples, including a survey of the
‘general population’ based on a cluster sample in 20 localities [59].
The study from Victoria used sequential serum sampling from an
existing study based on a stratified random cluster sample of
residents of the Melbourne metropolitan area [56]. Perhaps the
most ambitious study design was the post-sampling strategy in the
New Zealand study, which used a targeted cluster random sample
of patients registered at sentinel general practices included in the
influenza surveillance network in New Zealand [60].
In terms of the size of studies, the largest was the Hong Kong
study [10] which included more than 15,000 serum samples, while
the smallest was the study of pregnant women from Canada
involving less than 600 serum samples [57]. Except for the large
Figure 1. Flowchart for the review process.
doi:10.1371/journal.pone.0021828.g001
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study from Hong Kong [10], which used microneutralisation
assays, all other studies included in the review used haemagglu-
tination inhibition assays.
Age-specific infection
Estimates of pH1N1 infection in pre-school-age children (0-4
years) were reported only for New South Wales, Western
Australia, England, India, Norway and New Zealand (Table 2).
In Western Australia, New Zealand and regions of England that
experienced a substantial first pandemic wave, reported estimates
of the cumulative incidence of infection in pre-school aged
children ranged from approximately 16%–28%. Lower estimates
were found in Pune (India), Norway and some regions of England
(Table 2). Estimates of the cumulative incidence of pH1N1
infection in school-aged children, broadly 5–19 years of age, were
reported more frequently and were more similar around the
world, with reported point estimates of the cumulative incidence in
the range 34%–43% for most studies, although inconsistent results
were reported on whether higher rates of infection were likely to
occur in primary school-aged children (5–12 years) or older
children. Where the age groups were separated, investigators from
New South Wales and India reported higher infection rates in
older children, while investigators from Hong Kong reported
higher rates in younger children (Table 2).
Table 1. Outline of studies included in the review.
Study
location
pH1N1
circulation Sampling time points Summary of study design Comments a
Pre pH1N1 Post pH1N1
Australia [55] May - Sep 2009 April - early
May 2009
Oct-Dec
2009
Random plasma samples of blood donors. Age
stratified.
Pre-sample (n = 501) from two cities; post-sample
(n = 1307) from eight cities, including the site that
provided the pre-sample.
New South
Wales,
Australia [9]
June -Sep 2009 2007-2008 Aug-Sep
2009
Pre: serological samples submitted for non-
influenza testing. Post: residual diagnostic
plasma and sera.
Pre-sample (n = 474), post-sample (n = 1247).
Sampling strategy was different for pre and post
samples but both were convenience samples of
residual diagnostic sera.
Victoria,
Australia [56]
May-Aug 2009 2008-early
2009
Aug-Oct
2009
Pre: archive sera from healthy adults. Post:
opportunistic sample from existing cohort,
which used a stratified cluster sample and
sequential serological sampling.
Pre-sample n = 100. Post-sample n = 706
represented a 34% response rate.
Western
Australia,
Australia [8]
June-Sep 2009 Nov 2008-
May 2009
Aug-Nov
2009
Convenience samples of residual
diagnostic sera. Samples collected for
respiratory infections excluded. Only
children and pregnant women sampled.
Pre- and post-sampling strategies identical and
approximately balanced (n,450 children and
,200-300 pregnant women). Post sampling at two
time points; not all samples were post-pandemic.
Manitoba,
Canada [57]
April-July 2009 March 2009 Aug 2009 Random samples of frozen stored sera from
pregnant women tested as part of routine
pre-natal care
Pre- (n = 252) and post- (n = 296) samples were
approximately balanced and selected by the same
sampling strategy.
England [4] June-Aug 2009
(1st wave)
2008-April
2009
Aug-Sep
2009
Convenience sera from national sero-
epidemiology programme and residual
samples from biochemistry testing.
Pre- (n = 1403) and post- (n = 1954) samples were
approximately balanced and selected by the same
sampling strategy.
Hong
Kong [10]
Aug-Oct 2009 Before Aug
2009
After 15 Nov
2009
Convenience samples of blood donors,
hospital outpatients and an existing
paediatric cohort.
Blood donors n = 12,217. Hospital outpatients
n = 2,520. Paediatric cohort pre-sample n= 151,
post-sample n = 766. The paediatric cohort was part
of a vaccine trial. Samples were tested by MN assay.
Hong
Kong [58]
Aug-Oct 2009 2008 Nov - Dec
2009
Pre: residual virological diagnostic serum
samples (1 to .65 years). Post: residual
routine hepatitis B serum samples ( .9 years).
Pre-sample (n = 234), post-sample (n = 178). Small
unbalanced sampling strategy with no post-
pandemic samples for children under 9 years old.
Pune,
India [59]
June-Aug 2009 Jan 2005-Mar
2009
Aug-Dec
2009
Pre: stored residual sera for dengue
serology. Post: convenience samples of school
children, school and medical staff, railway
commuters, slum dwellers and the ‘general
population’.
Pre-samples (n = 222) yielded low seropositivity
(1%). Post-sampling strategy (n = 9233) not fully
detailed and included repeat sampling in some
groups. The ‘general population’ survey employed a
cluster sample of households in 20 localities.
New Zealand
[60]
April-Sep 2009 Before 22
April 2009
Nov 2009-
March 2010
Pre: residual diagnostic sera from two
laboratories. Post: targeted stratified random
sample of patients registered at
sentinel general practices.
Pre-sample n= 521. Post-sample n = 1156. Sentinel
practices were involved in surveillance of influenza-
like illness. A health care worker survey was not
included in this review.
Norway [61] July-Aug 2009;
Oct –Nov 2009
August 2008 Aug 2009
and Jan 2010
Three age and geographically representative
residual serum panels: pre-pandemic August
2008 (n = 689), post-pandemic panel August
2009 (n = 2116), post-national vaccination
campaign January 2010 (n = 541).
August 2009 post-pandemic sample indicated
minimal pH1N1 antibodies, attributed to small first
wave in Norway. Unable to distinguish between
antibodies from natural infection or vaccination in
January sample.
Singapore [62] June-Sep 2009 Before
June 27
2009
Aug-Oct
2009
Sequential serological sampling from four
cohorts: an existing community cohort,
military conscripts, hospital staff, and long
term care facility staff and residents.
Only the community cohort of persons aged 21-75
years (n = 838) was used in this review. The cohort
was established to study aspects of chronic
diseases.
aAll studies used haemagglutination inhibition assays to assess infection unless indicated in the comments.
doi:10.1371/journal.pone.0021828.t001
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All included studies reported estimates of infection in adults.
Again these were similar, in the range of approximately 9%–10%,
where the reported age group ranged from 16–18 years up to 64
years, although no significant infection appeared to have occurred
in adults in England during the first pandemic wave [4]. Where
age groups were separated, all investigators reported higher
infection rates in younger adults. New Zealand investigators
reported approximately 15% of adults aged 20–39 years had been
infected, whereas the estimate for this age group from the large
Hong Kong study was approximately 12% (Table 2). Where it was
measured, infection in adults older than 60 years was negligible, in
the range 2%–3%. The reported estimates of infection in pregnant
women were approximately 9% in Canada and 10% in Western
Australia, not different to the estimates for adults of all ages, or for
the estimates of similar aged adults in the large Hong Kong study
(Table 2).
Because few studies reported estimates of infection in children,
only the studies from Hong Kong, New South Wales and New
Zealand reported estimates of infection for the entire population.
The reported estimates were weighted by age and, in New
Zealand, by ethnicity, to represent the population and ranged
between approximately 11%–18% (Table 2).
Re-calculated estimates of the cumulative incidence of
infection
As described in the methods we re-calculated the cumulative
incidence of infection, where this was possible from the data
provided in the original study, inflating the final sero-prevalence
estimate by 10% to account for infections that may have been
missed by serology, and performing direct age-standardisation of
the estimates for each country or state. This resulted in some
minor changes to the estimates of the cumulative incidence of
infection, such as a slightly higher estimate of infection in the New
Zealand population (18% reported compared to 21% re-
calculated) and New South Wales (16% reported compared with
19% re-calculated). Most other re-calculated estimates were
similar to the reported estimates (Table 3). However when we
re-estimated 95% confidence intervals for the re-calculated
cumulative incidence of infection for children, adults and all ages,
we found that the smaller studies had substantial uncertainty about
the re-estimated cumulative incidence of infection (Figure 2).
Supporting findings from excluded studies
We further reviewed formally excluded studies to see if any of
them provided support for our findings. Where there was evidence
Table 2. Reported age-specific cumulative incidence of infection for studies included in the review.
Study Location Cumulative incidence (%) of infection by age groups (95% confidence interval [CI])
Pre-school aged children School aged children Adults All ages
Australia [55] Not reported Not reported 10.0% (CI not reported), 16-78y Not reported
New South Wales,
Australia [9]
15.6% (9.9-21.4), ,5y 9.8% (0.0-15.9), 5-11y
34.5% (24.0-44.7), 12-17y
8.8% (CI not reported), 18-$85y 15.6% (estimate weighted by age and
geographic region, CI not reported)
Victoria, Australia [56] Not reported Not reported 10.0% (CI not reported), 18-64y Not reported
Western Australia [8] 25.4% (18.6-33.4), 1-4y 39.4% (29.8-48.5), 5-19y 10.2% (4.1-17.1), 21-45y
(pregnant women only)
Not reported
Manitoba, Canada [57] Not reported Not reported 8.6% (3.2-13.7), 16-43y
(pregnant women only)
Not reported
London & West
Midlands, England [4]a
21.3% (8.8-40.3), ,5y 42.0% (26.3-58.2), 5-14y 6.2% (-2.8-18.7), 25-44y
-2.7% (-10.3-7.1), 45-64y
0.9% (-88.8-13.3), $65y
Not reported
Hong Kong [10] Not reported 43.4% (37.9-47.6), 5-14y
15.8% (8.2-22.1), 15-19y
11.8% (8.4-14.7), 20-29y
4.3% (0.9-7.5), 30-39y
4.6% (1.0-7.9), 40-49y
4.0% (1.1-7.5), 50-59y
10.7% (9.0-12.0)
Hong Kong [58] Not reported 23% (CI not reported), 10-19y 4% (CI not reported), 20-29y
9% (CI not reported), 30-39y
0% (CI not reported), 40-49y
-14% (CI not reported), 50-65y
-17% (CI not reported), .65y
Not reported
Pune, India [59] 7.4% (3.2-11.6), ,5y 20.0% (17.2-22.7), 5-9y
26.7% (24.3-29.2), 10-14y
42.2% (36.1-48.3), 15-19y
6.0% (5.1-6.9), $20y
(population)
10.7% (6.2-15.3)
(school staff)
Not reported
New Zealand [60] 23.5% (CI not reported), 1-4y 32.7% (CI not reported), 5-19 y 14.7% (CI not reported), 20-39y
13.7% (CI not reported), 40-59y
2.2% (CI not reported), $60y
18.3% (age and ethnicity adjusted,
CI not reported)
Norway [61] 0% (CI not reported), #2y 0% (CI not reported), 3-9y
4.9% (CI not reported), 10-19y
3.7% (CI not reported), 20-29y
0% (CI not reported), 30-49y
1.3% (CI not reported), 50-64y
-1.6% (CI not reported), 65-79y
3.2% (CI not reported), .80y
1.5% (CI not reported)
Singapore [62] Not reported Not reported 13% (11-16), $20y Not reported
aOnly the region of London and the West Midlands is presented, as there was minimal pH1N1 circulation in other regions [4].
doi:10.1371/journal.pone.0021828.t002
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of low pre-pandemic seroprevalence from a study in a similar
population base when a study reported only post-pandemic samples,
we assumed that the related pre-pandemic studies might apply to
the post-pandemic estimates in that population. When there were
only post-pandemic results for children, we assumed that pre-
pandemic titres may have been effectively zero, given this was found
in some of the included studies. Although we excluded six studies
from China, four of these studies provided potentially useful
estimates of infection (Table S1). Prior to circulation of pH1N1,
only about 2% of the resident population of Guangxi province of
China had cross-reacting pH1N1 antibodies [32]. This study had
been excluded because it only estimated seroprevalence prior to the
circulation of pH1N1. However if this pre-pandemic seroprevalence
were true for all of China, two serosurveys from Beijing that only
Table 3. Estimated age-standardized cumulative incidence of pandemic H1N1 influenza infection in ten studiesa.
Study Location Age group (years) Cumulative incidence of infection (%) (95% CI)
Australia [55] $16 10.7 (4.2, 17.2)
New South Wales, Australia [9] All 19.2 (4.4, 34.0)
Victoria, Australia [56] 18-64 11.3 (4.3, 18.3)
Western Australia [8] 1-19 40.5 (1.5, 79.4)
Englandb[4] All 11.1 (4.3, 17.9)
Hong Kong [10] 5-59 12.3 (4.3, 20.3)
India [59] 0-19 26.2 (3.6, 48.9)
New Zealand [60] $1 21.3 (4.2, 38.3)
Singapore [62] $24 13.7 (4.4, 24.9)
Norway [61] All 1.5 (1.1, 1.8)
aTwo of 12 studies were excluded due to the selective sample (only pregnant women) in the Canadian study [57] and the small sample size in one Hong Kong study
[58].
bAge-standardized cumulative incidence in the region of London and the West Midlands was used, as there was minimal pH1N1 circulation in other regions [4].
doi:10.1371/journal.pone.0021828.t003
Figure 2. Cumulative Incidence of Infection (95% CI).
doi:10.1371/journal.pone.0021828.g002
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estimated infection post pH1N1 circulation, might provide
representative estimates of infection in China. An age-weighted
estimate of the cumulative incidence of infection in the Beijing
population was reported as 14% [33], with estimates of 25% in
children 0–5 years and 34% in children 6–15 years from another
Beijing study [35]. These estimates are consistent with both the age-
specific and population estimates of pH1N1 infection from the
studies included in the review. A study of 200 blood donors aged
19–55 years from Guangzhou, China [36], excluded because of the
absence of pre-pandemic testing, reported a post-pandemic sero-
prevalence of 11%. This would be consistent with other studies only
if the pre-pandemic sero-prevalence in these blood donors was
effectively zero.
In another brief report from Beijing, excluded from this review
because of no pre-pandemic testing [31], the seroprevalence in
persons (age not specified) who had not received a pandemic
vaccine increased from approximately 14% to 28% between late
December 2009/early January 2010 and March 2010.
In a study from the US, excluded because of unequal pre- and
post-samples structures [52], it is possible to use the post-pandemic
estimates to assess the cumulative incidence of infection in children
if we assume that pre-pandemic titres were zero. Collected 2–4
weeks after the second wave from 846 persons aged 1 month to 90
years, serum samples indicated 28% of children aged 0–9 years
were sero-positive for pH1N1 and 45% of the 10–19 years age
group were reported as seropositive. The numbers tested in each
age group were not reported and it was not possible to re-calculate
confidence intervals. Nonetheless these point estimates of the
cumulative incidence of infection in these age groups are
consistent with those from the included studies.
Discussion
From a search for serosurveys published within a year of the end
of the first pandemic wave in the northern hemisphere and the end
of the season in which pH1N1 predominated in the southern
hemisphere, we found 12 studies that estimated the cumulative
incidence of pH1N1 infection. A further five studies, excluded
because they did not provide both pre- and post-pandemic
estimates, provided supportive estimates of the cumulative incidence
of infection. The exclusion of the majority of original non-duplicate
studies identified by our search illustrates the problems of
conducting adequate sero-surveys on short notice, especially when
sero-surveys were not planned as an element of pandemic
evaluation. We needed to adopt relaxed criteria on the assessment
of sampling strategies in order to include the final 12 studies. In
particular no sample was random, although the routinely collected
serum samples from Norway were representative of age and region
[61]; there were only two cohort studies - in Hong Kong [10] and
Singapore [62]; pre- and post-pandemic sampling was usually
unbalanced, with more extensive sampling post-pandemic; and
timing of the post-pandemic samples was not always optimal,
sometimes being prior to the end of pH1N1 circulation [8]. The
increase in the reported seroprevalence of an antibody titre .40
amongst unvaccinated persons in Beijing between December 2009
and March 2010 illustrates the importance of sample timing [31].
Moreover even the use of standard serological assays apparently did
not guarantee detection of all infected persons. Ten percent of 881
patients fromHongKong confirmed to have pH1N1 infection by PCR
testing had a neutralising antibody titre,40 [12] and would have been
below the conventional cut-off used to determine seroprotection. In this
study being afebrile at presentation was associated with a lower titre
(p=0.04), suggesting that some afebrile or completely asymptomatic
infections may have been missed – even in the serosurveys. Use of
antiviral treatment was associated with low convalescent antibody titres
[63] further potentially affecting the results of serologic studies in
countries which made substantial use of antiviral treatment. We
attempted to adjust for these findings in re-calculating estimates of the
cumulative incidence of infection. We also re-calculated confidence
intervals, based on the assumption of simple random sampling. These
confidence intervals provide an indication of the relative uncertainty of
the point estimates of the cumulative incidence from the included
studies.
Findings from this study
Given these important reservations, we found that, with the
exception of pre-school aged children, the reported age-specific
estimates of infection with pH1N1 were similar in all studies where
there had been a significant first wave of infection, in the range of
34%–43% for school-aged children and around 10% for adults,
but much lower for adults aged at least 60 years. Where the
cumulative incidence of infection could be estimated for the
population of all ages, it was reported to range from 11% in Hong
Kong [10] to 18% in New Zealand [60], with an intermediate
estimate of 16% in New South Wales [9]. A study from Beijing,
excluded because of the absence of pre-pandemic sampling,
reported infection in people aged 0–$60 years of 14% [33]. Re-
calculation of the cumulative incidence of infection in the whole
population resulted in slightly higher estimates in the range 11%
(4%–18%) in England to 21% (4%–38%) in New Zealand.
A study from Iran reported post-pandemic titres.40 in 50–60%
of children aged from 0–19 years [41]. No pre-pandemic testing was
performed and this study was excluded from the review. If the
proportion of pre-pandemic titres .40 was effectively zero in Iran,
as it appears to have been in many other countries where testing of
children was done, the cumulative incidence of infection in Iran
would be the highest of all reported countries. Of interest is that all
age groups in this study were recorded as having 50–60% of tested
persons with a pH1N1 titre .40.
The pandemic in the southern hemisphere, occurring during
the expected influenza season, probably resulted in more uniform
infection throughout the population than did the first and second
pandemic waves in the northern hemisphere, which were
characterised by variable infection rates between countries, such
as England [4] and Norway [61] and within countries [4,37,43].
Nonetheless this review confirms that cumulative incidence of
infection during the first and second waves prior to the availability
of a pandemic specific vaccine anywhere in the world, fell well
below the assumptions of an upper estimate of a 50% clinical
attack rate that had informed the pandemic planning of the
United Kingdom and other countries [64,65,66].
The lower than anticipated cumulative incidence was likely due
to the significant number of older people protected by neutralising
antibodies that cross-reacted with pH1N1 [2,38,42,50]. Indeed
from the serosurveys it appears as if infection was not common,
even in adults aged .40 years. Effectively a small proportion of
infection in a large proportion of the population resulted in lower
than expected estimates for the cumulative incidence of infection
in the whole population. The review also confirms that school-
aged children were most frequently infected with pH1N1,
presumably reflecting mixing patterns and relative immunological
naivety in this age group.
Study design and sample size
The studies ranged in size from many thousands of serum samples,
such as those in India [59] andHong Kong [10], to hundreds of serum
samples, such as the study of pregnant women in Canada [57].
Convenience sampling of residual diagnostic sera was the most
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common single approach to sampling in these studies. Residual
samples are used extensively throughout the world to evaluate
immunisation programs [61,67], and one previous study has suggested
that residual diagnostic samples gave similar estimates of immunity to a
range of vaccine preventable diseases as were obtained by a random
cluster sample [68]. While residual diagnostic samples are limited by
potential biases relating to risk of infection and vaccination history in
the predominantly inpatient population from which they are typically
drawn, similar estimates of the cumulative incidence of infection were
obtained using sera from healthy blood donors.
Studies in Hong Kong [10] and Singapore [62] were able to
take advantage of existing cohorts. Results from the cohort study
in Hong Kong were similar to the results from the cross-sectional
surveys in that city and the results from the adult cohort in
Singapore were similar to results for adults from a range of other
sampling strategies around the world. Study design and sample
size may not have been as critical as theoretical considerations
would have suggested, although the larger samples resulted in
much better precision of the point estimates, as shown by our re-
estimates of the confidence intervals. It has been suggested post-
pandemic sero-prevalence surveys need to test thousands of
specimens for their results to be informative. [20]
A somewhat surprising result from the review was the similarity
of point estimates of cumulative incidence from large well designed
studies to those obtained from smaller studies using residual sera.
The ideal study design would recruit a longitudinal cohort of
randomly selected people of all ages. Comparison of results from
this review with anticipated ideal design studies will provide a
more definitive answer to the question of whether samples of
residual diagnostic sera are adequate to determine evidence-based
policy for influenza vaccination.
Implications from our findings
Compared to seasonal influenza [69], a higher proportion of
asymptomatic infection for pH1N1 has been suggested [22].
Moreover some studies suggested a substantial proportion of
infected people did not present for medical attention [4,60]. Using
results from their serosurveys and including information from
other studies, investigators have suggested the case fatality ratio
(CFR) for pH1N1 may have varied between 0.01% [55] and
0.008% [60]. Although these CFR estimates are probably based
on under-estimates of death due to pH1N1, they are two orders of
magnitude lower than estimates of the CFR up to 2% that have
been widely accepted for the pandemic of 1918–19.
If serological studies are to be sufficiently timely to inform policy,
they need to be collected routinely, as is done in Norway [61] and the
UK [4]. However serological studies are most informative towards the
end of the pandemic. Other methods for estimating cumulative
infection of pH1N1 infection earlier in the pandemic were based on
existing surveillance systems. Comparisons of estimates from these
systems with those from serological studies in Singapore showed that
modelled estimates of the cumulative incidence of pH1N1 infection
from laboratory-supported sentinel surveillance schemes were similar
to those from serological surveys [70], suggesting that modelling may
have an important role in the early estimates of incidence and
cumulative incidence.
In conclusion we found that serological studies that estimated
the cumulative incidence of pH1N1 infection around the world
confirmed the findings from surveillance that school-aged children
were the most commonly infected age group and older adults were
relatively spared. Serological studies need to be routine in order to
be sufficiently timely to provide support for decisions about
vaccination and revised pandemic plans might consider a more
integrated role for serological studies.
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